Assessment of the association of HLA alleles, related TCR repertoire and cutaneous adverse reactions in Chinese Han population

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025285

Enrollment

Unknown

Registered

2019-08-21

Start date

2014-03-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cutaneous adverse drug eruptions

Interventions

tanshinone/minocyclin/methimazole/metronidazole/levofloxacin-induced-drug-eruptions patients:Extraction DNA from subject's peripheral blood and using PCR to genotype HLA class I alleles. Isolation of

tanshinone/minocyclin/methimazole/metronidazole/levofloxacin-tolerant volunteers:Extraction DNA from subject's peripheral blood and using PCR to genotype HLA class I alleles. Isolation of the PBMC, ex

normal individuals:Extraction DNA from subject's peripheral blood and using PCR to genotype HLA class I alleles. Isolation of the PBMC, extraction of RNA and reverse transcription to cDNA. PCR and TCR

Eligibility

Sex/Gender

All

Age

14 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Males and females aged between 14 to 80 years; 2. Offer written informed consent and willing and able to comply with all aspects of the protocol.

Exclusion criteria

Exclusion criteria: Patients with a history of blood coagulation dysfunction disorders.

Design outcomes

Primary

Measure	Time frame
HLA-A/B/C;TCR immunoscope spectratyping;	—

Countries

China

Contacts

Public ContactXiaoqun Luo

Huashan Hospital Affiliated to Fudan University

luoxiaoqun913@126.com+86 52889999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026